Literature DB >> 3465030

Norfloxacin treatment in complicated urinary tract infection.

J B Boerema, H K van Saene.   

Abstract

Twenty-four patients with complicated urinary tract infections were treated with norfloxacin for three months. Group I (n = 12), received 400 mg b.i.d. during three months and Group II (n = 12) received 400 mg b.i.d. during one month, followed by 400 mg as a single dose for two months. Most of the infections (67%), were due to Pseudomonas spp. A bacteriological cure rate of 75% (9/12) and 92% (11/12) in groups I and II, respectively, was achieved after three months therapy. One month after cessation of therapy patients were free of their initial infection in 75% (9/12) and 83% (10/12), respectively. Clinical cure was achieved in 75% of the patients in both groups. This remained the case in group I after cessation of treatment. In group II, 50% remained free of symptoms one month post-therapy. Both clinical and laboratory adverse reactions were minor and none of the patients discontinued treatment due to side effects. Norfloxacin therapy was effective in the long term treatment of chronic recurrent infections in patients with severe urological conditions. Prevention of relapse or reinfection from the primary endogenous faecal reservoirs (Enterobacteriaceae), was probably due to the high effect of norfloxacin against these organisms. The relatively good effect on pseudomonas infection in this group of patients, was probably due to a high concentration of norfloxacin in the urine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3465030

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  6 in total

1.  Use of fluoroquinolone antimicrobial agents by cardiovascular and cardiopulmonary surgeons.

Authors:  H C Neu
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  The future of new oral antibiotics including the quinolones.

Authors:  M G Bergeron
Journal:  CMAJ       Date:  1988-01-01       Impact factor: 8.262

3.  Comparison of norfloxacin versus nalidixic acid in therapy of acute urinary tract infections.

Authors:  L K Selin; G K Harding; M J Thomson; J K Kennedy; B A Urias; A R Ronald
Journal:  Can J Infect Dis       Date:  1990

4.  Complicated urinary tract infection in adults.

Authors:  L E Nicolle
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-11       Impact factor: 2.471

5.  Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.

Authors:  R Mattina; C E Cocuzza; M Cesana
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

Review 6.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.